Endometriosis, a debilitating condition affecting 1 in 10 women, often goes undiagnosed or overlooked. Women with endometriosis also face a heightened risk of developing ovarian cancer. Understanding this connection and the overlapping symptoms is vital for earlier detection and better outcomes.

What is Endometriosis?
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, attaching to organs like the ovaries, fallopian tubes, and pelvic lining. This can cause pain, inflammation, and scarring. (mayoclinic.org)
Endometriosis affects about 10% of reproductive-aged women globally. (nichd.nih.gov) Beyond physical symptoms, it impacts mental health and quality of life, with many women waiting years for diagnosis. Research also links it to an increased risk of ovarian cancer. (cancer.org)
What is Ovarian Cancer?
Ovarian cancer originates in the ovaries, the organs responsible for producing eggs and hormones like estrogen and progesterone. It is the most lethal gynecological cancer, often called the "silent killer" due to vague symptoms that usually appear in advanced stages.
Ovarian cancer's deadliness lies in its late detection. The 5-year survival rate drops from over 90% for early-stage diagnosis to less than 30% for advanced cases, emphasizing the need for better awareness and early detection. Epithelial ovarian cancer accounts for 90% of cases. Risk factors include age, family history, and genetic mutations such as BRCA1 and BRCA2.
The Connection Between Endometriosis and Ovarian Cancer
Women with endometriosis are at a higher risk of developing ovarian cancer, particularly endometriosis-associated ovarian cancers (EAOCs) such as clear cell and endometrioid carcinomas. (JAMA)
The link between these conditions is believed to stem from chronic inflammation, oxidative stress, and hormonal imbalances associated with endometriosis, which may drive cellular changes leading to cancer (frontiersin.org). Genetic mutations such as ARID1A and PIK3CA are often found in both endometriosis lesions and ovarian cancer tumors, suggesting shared molecular pathways. (nature.com)
Regular monitoring for ovarian cancer is crucial for women with endometriosis, as early detection significantly improves outcomes. However, current monitoring modalities are of limited effectiveness in detecting early ovarian cancer.
Advancing Diagnostics: Tools and Challenges
Innovative diagnostics are transforming women’s health. Glycoform biomarkers, molecular structures formed by altered glycosylation, can differentiate benign and malignant conditions, improving early detection of ovarian cancer. Tools like the Lectin Magnetic Bead Array-Mass Spectrometry (LeMBA-MS) platform enable simultaneous monitoring of multiple glycoforms in blood samples, streamlining the development of non-invasive tests.
However, challenges remain. Large-scale clinical trials are needed to validate biomarkers and standardize protocols. Integrating these tools into healthcare systems requires clinician training, infrastructure improvements, and affordability considerations. (bmj.com) (who.int)
Collaboration between researchers, clinicians, and policymakers is essential to overcome barriers and ensure equitable access to these advancements, ultimately improving outcomes for women worldwide.
Call to Action
It’s time to prioritize early detection and proactive care for women with endometriosis to mitigate their risk of ovarian cancer. If you or someone you know is managing endometriosis, speak to a healthcare professional about regular monitoring and advanced diagnostic options. Together, we can work toward better outcomes and improved quality of life for all women.
Â
Table comparing symptoms of endometriosis and ovarian cancer
Symptom | Endometriosis | Ovarian Cancer |
Pelvic Pain | Chronic, cyclical pain, often worsening during menstruation | Persistent or intermittent pelvic or abdominal pain |
Menstrual Irregularities | Heavy or prolonged periods (menorrhagia) | Irregular periods, though less common |
Abdominal Bloating | Occasional, related to hormonal changes | Frequent, progressive, unrelated to diet |
Painful Intercourse (Dyspareunia) | Common, due to endometrial tissue near reproductive organs | Less common, may occur in advanced stages |
Digestive Issues | Rare, may include mild gastrointestinal discomfort | Persistent nausea, indigestion, or loss of appetite |
Urinary Symptoms | Rare, may include bladder irritation | Frequent urination or a constant urge to urinate |
Fatigue | Common, due to chronic inflammation and pain | Common in advanced stages due to systemic effects |
Infertility | Frequent, a key complication of untreated endometriosis | Rare, unless caused by advanced disease or treatment |
Weight Changes | Rare, not a characteristic symptom | Unexplained weight loss or gain in later stages |
Pain During Bowel Movements | Possible, if endometrial tissue is near the rectum | Rare, may occur if cancer compresses the bowel |
Regular Monitoring Options
Routine Pelvic Examinations:
Regular pelvic exams can help identify abnormalities in the pelvic region, though these exams are limited in detecting deep endometriosis or early-stage ovarian cancer.
Ultrasound Imaging (Transvaginal or Pelvic):
Frequently used to detect ovarian masses or cysts. While helpful, it cannot definitively differentiate between benign and malignant growths.
CA125 Blood Test:
A blood test to measure levels of CA125, a protein that can be elevated in ovarian cancer. However, it is not highly specific or sensitive, especially in early-stage disease.
Symptom Tracking:
Women are encouraged to monitor and report persistent symptoms like pelvic pain, bloating, or changes in menstrual patterns.
Advanced Diagnostic Options
Magnetic Resonance Imaging (MRI):
Used for detailed visualization of pelvic and abdominal structures, including deep endometriosis.
Laparoscopy:
A minimally invasive surgical procedure that allows direct visualization of endometriosis lesions and biopsies for definitive diagnosis.
Glycoform Biomarkers:
Emerging blood-based tests that analyze glycoforms—molecular structures resulting from altered glycosylation—are showing promise for detecting ovarian cancer early.
Next-Generation Biomarker Panels:
Panels combining multiple biomarkers (e.g., proteins, glycoforms, genetic markers) are being developed for greater diagnostic accuracy.
Molecular Imaging Techniques:
Advanced imaging technologies, like PET-CT scans with targeted tracers, are being explored for their ability to identify early malignant transformations.
Genetic Testing:
Testing for BRCA1, BRCA2, and other genetic mutations can assess inherited risk and guide personalized monitoring plans.
.
Comments